AbbVie's Bold $1.4 Billion Bet: The Alzheimer's Breakthrough Investors Have Been Waiting For

By Yahoo! Finance | Oct 28, 2024 at 01:17 PM EST

AbbVie's strategic acquisition of Aliada Therapeutics for $1.4 billion is a significant move into Alzheimer's innovation. The acquisition enhances AbbVie's R&D capabilities with cutting-edge technology targeting amyloid plaques, strengthening its position in the neuroscience field amidst growing demand for CNS treatments.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.